Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
4.990
-0.090 (-1.77%)
At close: Feb 21, 2025, 4:00 PM
5.23
+0.24 (4.81%)
After-hours: Feb 21, 2025, 7:36 PM EST
Olema Pharmaceuticals Employees
Olema Pharmaceuticals had 74 employees as of December 31, 2023. The number of employees decreased by 12 or -13.95% compared to the previous year.
Employees
74
Change (1Y)
-12
Growth (1Y)
-13.95%
Revenue / Employee
n/a
Profits / Employee
-$1,657,824
Market Cap
370.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 74 | -12 | -13.95% |
| Dec 31, 2022 | 86 | 12 | 16.22% |
| Dec 31, 2021 | 74 | 37 | 100.00% |
| Dec 31, 2020 | 37 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
OLMA News
- 4 days ago - Olema Oncology Appoints Shawnte M. Mitchell, J.D. - GlobeNewsWire
- 18 days ago - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
- 2 months ago - Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 2 months ago - Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor - GlobeNewsWire
- 3 months ago - Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium - GlobeNewsWire